Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arvelle Therapeutics

Request full access

A biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Zug, SwitzerlandFounded 2019Biotech & Life Sciences

About Arvelle Therapeutics

Arvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company's primary product is cenobamate, an investigational anti-seizure medication aimed at treating drug-resistant focal onset seizures in adults. This medication has been designated as a Promising Innovative Medicine (PIM) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Arvelle operates in the European healthcare market, targeting patients suffering from CNS disorders, particularly those with epilepsy who have not responded well to existing treatments. The company collaborates with healthcare professionals (HCPs) and partners like Durbin to ensure the distribution and accessibility of their medication across Europe.

Arvelle's business model revolves around the development, regulatory approval, and commercialization of cenobamate. They generate revenue through the sale of this medication to healthcare providers and institutions. By focusing on a niche market with significant unmet medical needs, Arvelle aims to establish a strong presence in the CNS disorder treatment landscape.

The company actively participates in industry conferences, such as the Jefferies Virtual 2020 Healthcare Conference and the Jefferies 2020 London Healthcare Conference, to present their progress and engage with potential investors and partners. These activities help Arvelle to build credibility and attract the necessary funding to support their ongoing research and development efforts.

In summary, Arvelle Therapeutics is dedicated to bringing new hope to patients with CNS disorders through innovative treatments like cenobamate. Their strategic partnerships and focus on a specialized market position them as a promising player in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
18
Open positions
None listed
Dealroom signal
59.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jan 2021 $960M $960M Angelini Pharma —
SERIES AOther financing May 2020 $43M $171M H.I.G. HealthBridge · NovaQuest Capital Management · Andera Partners · BRV Capital Management ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Arvelle Therapeutics website traffic

Latest recorded traffic for Arvelle Therapeutics is 390 monthly website visits, up 333.3% over the last three months. Arvelle Therapeutics's team grew 0% over the past year.

Latest monthly visits390 3-month web change+333.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Arvelle Therapeutics in the Zug ecosystem

Live from Dealroom

The Arvelle Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • EQT Life Sciences
  • NovaQuest Capital Management
  • BRV Capital Management
  • HIG Capital
  • Andera Partners
  • H.I.G. HealthBridge
  • F-Prime

Series B and later1 investor entered at this stage

  • Sio Gene Therapies

Other known investors1 additional known investor

  • Angelini Pharma
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇭 Switzerland75%
🇺🇸 United States25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Arvelle Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arvelle Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.